Lipella Pharmaceuticals INC 10-Q quarterly reports

Lipella Pharmaceuticals reported increased net losses and significant cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern, following its delisting from Nasdaq.

Lipella Pharmaceuticals Inc. reported increased net losses and was delisted from Nasdaq, raising substantial doubt about its ability to continue as a going concern, despite clinical progress.

Lipella Pharmaceuticals announces its Q1 2025 financial results, showing a net loss of $1.31 million and ongoing efforts to maintain Nasdaq compliance.

Lipella Pharmaceuticals reported a net loss of $1.44 million for the third quarter of 2024, with ongoing clinical development activities and Nasdaq compliance issues impacting the company.

Lipella Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting progress in clinical trials and ongoing research and development efforts.

Lipella Pharmaceuticals reported a net loss of $1.19 million for the first quarter of 2024 and is addressing a Nasdaq minimum bid price compliance issue.